Clincosm LogoSign in Get a demo

Efficacy and Safety of Tenoten in the Treatment of Children With Anxiety Disorders

Sponsor
Materia Medica Holding (Industry)
Overall Status
Completed
CT.gov ID
NCT05605938
Collaborator
(none)
98
Enrollment
5
Locations
2
Arms
15
Actual Duration (Months)
19.6
Patients Per Site
1.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Purpose of the study:

• evaluate the efficacy and safety of Tenoten for children in children with anxiety disorders.

Condition or Disease Intervention/Treatment Phase
  • Drug: Tenoten for children
  • Drug: Placebo
 Phase 4

Detailed Description

Design: a multicenter, double-blind, placebo-controlled, parallel-group randomized clinical trial.

The study includs children of both sexes aged 5 to 15 years who were diagnosed by a neurologist with an anxiety disorder (according to the ICD-10, one of the variants of an emotional disorder with an onset specific to childhood - F 93).

After a parent/legal representative signed an informed consent form for participation in the clinical trial at the screening visit (Visit 1, Day 0), patients underwent an initial examination, including medical history, assessment of vital signs, and physical examination; concomitant therapy was recorded. The initial severity of anxiety disorders (from mild to severe) was assessed using a scale for assessing the severity of anxiety in children (G.P. Lavrentieva, T.M. Titarenko), using an anxiety test (R. Temple, V. Amen, M. Dorki) and Spence Children's Anxiety Scale (SCAS). If the inclusion criteria were met and no exclusion criteria were met, the patient was included in the study and randomized to one of the groups: Tenoten for children or Placebo (day 0, visit 1). In the course of treatment, patients made 3 visits to the doctor within 12 weeks (at 4, 8 and 12 weeks), during which the dynamics of the severity of anxiety disorders were recorded using an anxiety test (R. Temple, V. Amen, M. Dorki) and SCAS; vital signs and physical examination were performed, prescribed and concomitant therapy were controlled. At visit 4 (week 12), doctor assessed the therapeutic dynamics and treatment side effects by the end of the treatment period in scores on the Clinical Global Impression (CGI) scale.

Study Design

Study Type:
Interventional
Actual Enrollment :
98 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
double-blind placebo-controlled randomizeddouble-blind placebo-controlled randomized
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Multicenter Double-blind Placebo-controlled Randomized Clinical Trial of the Efficacy and Safety of Tenoten for Children in 12-week Treatment of Children With Anxiety Disorders
Actual Study Start Date :
Jul 28, 2010
Actual Primary Completion Date :
Oct 28, 2011
Actual Study Completion Date :
Oct 28, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: Tenoten for children

1 tablet 3 times daily for 12 weeks. Route of administration: sublingual, the tablet should be held in the mouth until completely dissolved.

Drug: Tenoten for children
Oral administration
Placebo Comparator: Placebo

As per the Tenoten for children dosing regimen.

Drug: Placebo
Oral administration

Outcome Measures

Primary Outcome Measures

  1. Changes in SCAS scores [12 weeks]

    Spence Children's Anxiety Scale (SCAS).The study uses 3 scales: (1) for patients aged 5-7 years and (2) for patients aged 8-15 (both of them filled in by patient's legal representatives); (3) for patients aged 8-15 years (filled in by patient). Maximum total score of each scales is 114. A higher score reflects a higher level of anxiety

  2. Changes in severity of anxiety according to test of R.Temple, V.Amen, M.Dorky [12 weeks]

    The questionnaire is filled in by legal representative of patient. Each "yes" answer means 1 point. Severe anxiety 15-20 points; moderate 7-14 points; mild 1-6 points

  3. Percentage of patients who progress to milder anxiety disorders [12 weeks]

    Based on medical records

Secondary Outcome Measures

  1. Changes in anxiety disorder symptoms according to SCAS domains, depending on type of anxiety disorders [12 weeks]

    Based on medical records

  2. Comparison of mean CGI scores between study groups [12 weeks]

    Clinical Global Impression (CGI) scale consists of three subscales: severity of condition, overall degree of its improvement on 7-point system, and subscale of the efficacy index, which is calculated from the combination of one of four degrees of therapeutic effect (noticeable, moderate, minimal, no change) and severity of the side effect drug (absent, insignificant, significant, leveling therapeutic effect)

  3. Occurrence and characteristics of adverse events [12 weeks]

    Based on medical records. Occurrence, severity, relationship with medicine, outcomes of adverse events

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years to 15 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Children of both sexes aged 5 to 15 years inclusive.

  2. At least one of the diagnoses from ICD-10 Diagnosis Code F 93 - Emotional disorders with onset specific to childhood:

  • Separation anxiety disorder of childhood - F 93.0;

  • Phobic anxiety disorder of childhood - F 93.1;

  • Social anxiety disorder of childhood - F 93.2;

  • Generalized anxiety disorder of childhood - F 93.8.

  1. Mild to severe disease, with the severity assessed using the following scales:

  • Child Anxiety Scale of G.P. Lavrentieva and T.M. Titarenko;

  • anxiety test of R. Temple, V. Amen, M. Dorky;

  1. No signs of severe cognitive development deficiency, according to the investigator;

  2. No drug treatment for anxiety disorders within the last two weeks;

  3. Availability of singed informed consent from the legal representative of a child. In addition, patients aged ≥14 years are to sign a patient informed consent form.

Exclusion Criteria:

  1. Age under 5 or over 15 years;

  2. Decompensated somatic diseases that may affect the conduct of the trial;

  3. Severe residual signs of organic CNS injury;

  4. Hallucinations, delusions, and psychotic affective disorders;

  5. Mental retardation and oligophrenic-like impairment;

  6. Hypersensitivity to any components of the study drugs;

  7. Reluctance of a child or his/her legal representatives to participate in the clinical study;

  8. The patient's legal representative with drug abuse problems, alcoholism, or mental disorders;

  9. Participation in other clinical studies within 4 months prior to enrollment in the current trial.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Specialized Clinical Psychiatric Hospital # 1 Krasnodar Russian Federation 350007
2 Scientific Center for Mental Health of the Russian Academy of Medical Sciences Moscow Russian Federation 115522
3 Russian National Research Medical University named after N.I. Pirogov Moscow Russian Federation 117997
4 Scientific Center for Children's Health of the Russian Academy of Medical Sciences Moscow Russian Federation 119991
5 Institute of the Human Brain named after N.P. Bekhtereva Russian Academy of Sciences Saint Petersburg Russian Federation 197376

Sponsors and Collaborators

  • Materia Medica Holding

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Materia Medica Holding
ClinicalTrials.gov Identifier:
NCT05605938
Other Study ID Numbers:
  • MMH-TD-001
First Posted:
Nov 4, 2022
Last Update Posted:
Nov 4, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Anxiety Disorders

Study Results

No Results Posted as of Nov 4, 2022